Gil M. Labrucherie Buys 5,000 Shares of Septerna, Inc. (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie purchased 5,000 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were bought at an average cost of $5.85 per share, for a total transaction of $29,250.00. Following the acquisition, the chief financial officer now owns 30,000 shares in the company, valued at approximately $175,500. The trade was a 20.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Septerna Stock Performance

SEPN opened at $5.80 on Friday. Septerna, Inc. has a 1-year low of $4.17 and a 1-year high of $28.99. The stock has a 50 day simple moving average of $17.78.

Hedge Funds Weigh In On Septerna

Institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC bought a new stake in Septerna during the fourth quarter valued at about $25,000. New York State Common Retirement Fund purchased a new position in shares of Septerna during the 4th quarter valued at about $32,000. Legal & General Group Plc purchased a new position in shares of Septerna during the 4th quarter valued at about $42,000. Summit Investment Advisors Inc. bought a new position in shares of Septerna during the 4th quarter valued at approximately $45,000. Finally, BNP Paribas Financial Markets purchased a new stake in Septerna in the 4th quarter worth approximately $52,000.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on SEPN. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price objective on shares of Septerna in a research report on Tuesday, February 11th. TD Cowen initiated coverage on Septerna in a report on Tuesday, November 19th. They set a “buy” rating on the stock. Wells Fargo & Company downgraded Septerna from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $43.00 to $14.00 in a research note on Tuesday, February 18th. Finally, JPMorgan Chase & Co. began coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price objective for the company.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.